June 14, 2024 02:52 PM EDT

Rare pediatric disease vouchers face uncertain future after September

Zachary Brennan

Senior Editor

Congress has until the end of September to reauthorize a voucher program that’s meant to incentivize new drug development for rare pediatric diseases. But the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Rare pediatric disease vouchers face uncertain future after September

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Associate Director, Market Insights and Analytics

Celldex Therapeutics

Hampton, NJ, USA

FDA ships two Form 483s to Dr. Reddy’s for two separate sites in India

Peter Marks single-handedly approved Sarepta’s gene therapy — what does that mean for everyone else?

Three of Vertex’s islet cell therapy patients go insulin-independent

Bristol Myers wins approval for KRAS drug Krazati in colorectal cancer

Lilly’s Zepbound resolves sleep apnea in obese patients, furthering case for label expansion

AstraZeneca’s Truqap combo flops in Phase 3 triple-negative breast cancer trial

Rare pe­di­atric dis­ease vouch­ers face un­cer­tain fu­ture af­ter Sep­tem­ber

Senior Editor

Sign up to read this article for free.

more like this

Celldex Therapeutics

Hampton, NJ, USA

Rare pediatric disease vouchers face uncertain future after September